Neonmind’s NEO-002 artificial psilocybin candidate will likely be studied as a lower-dose treatment method to regulate and suppress affected person appetite. The company has secured pharmaceutical quality artificial psilocybin from Psygen and anticipates initiating a Period I/II proof-of-principle review for NEO-001 during the in close proximity to upcoming. Clearmind https://joanl543xma9.activosblog.com/profile